Increased antitumor effects using IL-2 with Anti-TGF-β reveals competition between mouse NK and CD8 T Cells

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 1709-1716

  Alvarez, Maite ^a   Bouchlaka, Myriam N ^b   Sckisel, Gail D ^a   Sungur, Can M ^a   Chen, Mingyi ^c   Murphy, William J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 6; LIVER ENZYME; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD95; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FAS LIGAND PROTEIN; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY A; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84905992207     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400034     Document Type: Article

References (54)

1. Sutlu, T., and E. Alici. 2009. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med. 266: 154-181.
2. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913.
3. Buyse, M., P. Squifflet, B. J. Lange, T. A. Alonzo, R. A. Larson, J. E. Kolitz, S. L. George, C. D. Bloomfield, S. Castaigne, S. Chevret, et al. 2011. Individual patient data meta-Analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 117: 7007-7013.
4. Peace, D. J., and M. A. Cheever. 1989. Toxicity and therapeutic efficacy of highdose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J. Exp. Med. 169: 161-173.
5. Steel, J. C., T. A. Waldmann, and J. C. Morris. 2012. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33: 35-41.
6. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24: 99-146.
7. Laouar, Y., F. S. Sutterwala, L. Gorelik, and R. A. Flavell. 2005. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 6: 600-607.
8. Ghiringhelli, F., C. Ménard, F. Martin, and L. Zitvogel. 2006. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214: 229-238.
9. Barao, I., A. M. Hanash, W. Hallett, L. A. Welniak, K. Sun, D. Redelman, B. R. Blazar, R. B. Levy, and W. J. Murphy. 2006. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA 103: 5460-5465.
10. Marcoe, J. P., J. R. Lim, K. L. Schaubert, N. Fodil-Cornu, M. Matka, A. L. McCubbrey, A. R. Farr, S. M. Vidal, and Y. Laouar. 2012. TGF-b is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat. Immunol. 13: 843-850.
11. Smith, A. L., T. P. Robin, and H. L. Ford. 2012. Molecular pathways: targeting the TGF-b pathway for cancer therapy. Clin. Cancer Res. 18: 4514-4521.
12. Penafuerte, C., and J. Galipeau. 2008. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol. Immunother. 57: 1197-1206.
13. Petrausch, U., S. M. Jensen, C. Twitty, C. H. Poehlein, D. P. Haley, E. B. Walker, and B. A. Fox. 2009. Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J. Immunol. 183: 3682-3689.
14. Nam, J. S., M. Terabe, M. Mamura, M. J. Kang, H. Chae, C. Stuelten, E. Kohn, B. Tang, H. Sabzevari, M. R. Anver, et al. 2008. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68: 3835-3843.
15. Perry, K., L. Wong, V. Liu, I. Park, Q. Zhang, V. Rejen, X. Huang, N. D. Smith, B. Jovanovic, S. Lonning, et al. 2008. Treatment of transforming growth factorbeta-insensitive mouse Renca tumor by transforming growth factor-beta elimination. Urology 72: 225-229.
16. Ogasawara, K., and L. L. Lanier. 2005. NKG2D in NK and T cell-mediated immunity. J. Clin. Immunol. 25: 534-540.
17. Hülper, P., W. Schulz-Schaeffer, C. Dullin, P. Hoffmann, J. Harper, L. Kurtzberg, S. Lonning, W. Kugler, M. Lakomek, and B. Erdlenbruch. 2011. Tumor localization of an anti-TGF-b antibody and its effects on gliomas. Int. J. Oncol. 38: 51-59.
18. Terabe, M., E. Ambrosino, S. Takaku, J. J. O'Konek, D. Venzon, S. Lonning, J. M. McPherson, and J. A. Berzofsky. 2009. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factorbeta monoclonal antibody. Clin. Cancer Res. 15: 6560-6569.
19. Hallett, W. H., E. Ames, M. Alvarez, I. Barao, P. A. Taylor, B. R. Blazar, and W. J. Murphy. 2008. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol. Blood Marrow Transplant. 14: 1088-1099.
20. Park, J., S. H. Wrzesinski, E. Stern, M. Look, J. Criscione, R. Ragheb, S. M. Jay, S. L. Demento, A. Agawu, P. Licona Limon, et al. 2012. Combination delivery of TGF-b inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater. 11: 895-905.
21. Barao, I., M. Alvarez, E. Ames, M. T. Orr, H. E. Stefanski, B. R. Blazar, L. L. Lanier, S. K. Anderson, D. Redelman, and W. J. Murphy. 2011. Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. Blood 117: 7032-7041.
22. Raziuddin, A., M. Bennett, R. Winkler-Pickett, J. R. Ortaldo, D. L. Longo, and W. J. Murphy. 2000. Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2(b) bone marrow cell allografts. Blood 95: 3840-3844.
23. Tietze, J. K., D. E. Wilkins, G. D. Sckisel, M. N. Bouchlaka, K. L. Alderson, J. M. Weiss, E. Ames, K. W. Bruhn, N. Craft, R. H. Wiltrout, et al. 2012. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood 119: 3073-3083.
24. Hallett, W. H., E. Ames, M. Motarjemi, I. Barao, A. Shanker, D. L. Tamang, T. J. Sayers, D. Hudig, and W. J. Murphy. 2008. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 180: 163-170.
25. Bouchlaka, M. N., G. D. Sckisel, M. Chen, A. Mirsoian, A. E. Zamora, E. Maverakis, D. E. Wilkins, K. L. Alderson, H. H. Hsiao, J. M. Weiss, et al. 2013. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J. Exp. Med. 210: 2223-2237.
26. Ling, H., X. Li, S. Jha, W. Wang, L. Karetskaya, B. Pratt, and S. Ledbetter. 2003. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J. Am. Soc. Nephrol. 14: 377-388.
27. Melder, R. J., B. L. Osborn, T. Riccobene, P. Kanakaraj, P. Wei, G. Chen, D. Stolow, W. G. Halpern, T. S. Migone, Q. Wang, et al. 2005. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol. Immunother. 54: 535-547.
28. Miller, J. S. 2013. Therapeutic applications: natural killer cells in the clinic. Hematology Am. Soc. Hematol. Educ. Prog. 2013: 247-253.
29. Hayakawa, Y., and M. J. Smyth. 2006. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176: 1517-1524.
30. Wojtowicz-Praga, S., U. N. Verma, L. Wakefield, J. M. Esteban, D. Hartmann, and A. Mazumder. 1996. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J. Immunother. Emphasis Tumor Immunol. 19: 169-175.
31. Schmitz, I., A. Krueger, S. Baumann, H. Schulze-Bergkamen, P. H. Krammer, and S. Kirchhoff. 2003. An IL-2-dependent switch between CD95 signaling pathways sensitizes primary human T cells toward CD95-mediated activationinduced cell death. J. Immunol. 171: 2930-2936.
32. Lee, S. H., K. S. Kim, N. Fodil-Cornu, S. M. Vidal, and C. A. Biron. 2009. Activating receptors promote NK cell expansion for maintenance, IL-10 production and CD8 T cell regulation during viral infection. J. Exp. Med. 206: 2235-2251.
33. Waggoner, S. N., M. Cornberg, L. K. Selin, and R. M. Welsh. 2012. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481: 394-398.
34. Soderquest, K., T. Walzer, B. Zafirova, L. S. Klavinskis, B. Polić, E. Vivier, G. M. Lord, and A. Martín-Fontecha. 2011. Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses. J. Immunol. 186: 3304-3308.
35. Fehniger, T. A., M. A. Cooper, and M. A. Caligiuri. 2002. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13: 169-183.
36. Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp, and A. K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623.
37. Alderson, K. L., Q. Zhou, V. Berner, D. E. Wilkins, J. M. Weiss, B. R. Blazar, L. A. Welniak, R. H. Wiltrout, D. Redelman, and W. J. Murphy. 2008. Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J. Immunol. 180: 2981-2988.
38. Berner, V., H. Liu, Q. Zhou, K. L. Alderson, K. Sun, J. M. Weiss, T. C. Back, D. L. Longo, B. R. Blazar, R. H. Wiltrout, et al. 2007. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13: 354-360.
39. Prabhu, N., A. W. Ho, K. H. Wong, P. E. Hutchinson, Y. L. Chua, M. Kandasamy, D. C. Lee, B. Sivasankar, and D. M. Kemeny. 2013. Gamma interferon regulates contraction of the influenza virus-specific CD8 T cell response and limits the size of the memory population. J. Virol. 87: 12510-12522.
40. Diaz-Guerra, E., R. Vernal, M. J. del Prete, A. Silva, and J. A. Garcia-Sanz. 2007. CCL2 inhibits the apoptosis program induced by growth factor deprivation, rescuing functional T cells. J. Immunol. 179: 7352-7357.
41. Elpek, K. G., M. P. Rubinstein, A. Bellemare-Pelletier, A. W. Goldrath, and S. J. Turley. 2010. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc. Natl. Acad. Sci. USA 107: 21647-21652.
42. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
43. Narni-Mancinelli, E., B. N. Jaeger, C. Bernat, A. Fenis, S. Kung, A. De Gassart, S. Mahmood, M. Gut, S. C. Heath, J. Estelle, et al. 2012. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science 335: 344-348.
44. Andrews, D. M., A. A. Scalzo, W. M. Yokoyama, M. J. Smyth, and M. A. Degli-Esposti. 2003. Functional interactions between dendritic cells and NK cells during viral infection. Nat. Immunol. 4: 175-181.
45. Piccioli, D., S. Sbrana, E. Melandri, and N. M. Valiante. 2002. Contactdependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195: 335-341.
46. Dowdell, K. C., D. J. Cua, E. Kirkman, and S. A. Stohlman. 2003. NK cells regulate CD4 responses prior to antigen encounter. J. Immunol. 171: 234-239.
47. Shi, F. D., and L. Van Kaer. 2006. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat. Rev. Immunol. 6: 751-760.
48. Paya, C. V., A. K. Patick, P. J. Leibson, and M. Rodriguez. 1989. Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus. J. Immunol. 143: 95-102.
49. Barber, M. A., T. Zhang, B. A. Gagne, and C. L. Sentman. 2007. NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J. Immunol. 178: 6140-6147.
50. Salem, M. L., and M. S. Hossain. 2000. In vivo acute depletion of CD8(+) T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells. Int. J. Immunopharmacol. 22: 707-718.
51. Ardolino, M., A. Zingoni, C. Cerboni, F. Cecere, A. Soriani, M. L. Iannitto, and A. Santoni. 2011. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 117: 4778-4786.
52. Priyadharshini, B., T. B. Thornley, K. A. Daniels, A. Cuthbert, R. M. Welsh, D. L. Greiner, and M. A. Brehm. 2013. Alloreactive CD8 T cells rescued from apoptosis during co-stimulation blockade by Toll-like receptor stimulation remain susceptible to Fas-induced cell death. Immunology 138: 322-332.
53. Li, J. H., D. Rosen, P. Sondel, and G. Berke. 2002. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology 105: 267-277.
54. Watt, S. V., D. M. Andrews, K. Takeda, M. J. Smyth, and Y. Hayakawa. 2008. IFN-gamma-dependent recruitment of mature CD27(high) NK cells to lymph nodes primed by dendritic cells. J. Immunol. 181: 5323-5330.